EMCURE PHARMACEUTICALS L (EMCURE)
companyActive threads
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike
Emcure Pharmaceuticals shares rose 10% to a new high of ₹2,180.80 on the BSE after Q2FY27 adjusted PAT climbed 29.3% YoY to ₹325.1 crore and revenue grew 24.3% to ₹2,820.5 crore, helped by strong international business. Jefferies raised its target price by 8% and remains positive on the near- to mid-term outlook, citing multiple growth drivers and operating-leverage benefits. The stock's circuit hit followed the guidance hike, with the profit figure up from ₹251.4 crore a year earlier.
Emcure Pharma approves merger of Zuventus and Emcutix subsidiaries
Emcure Pharma up over 3% as board approves merger of two subsidiaries Emcure Pharmaceuticals will merge its wholly owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, with itself under the proposed scheme. Listen to This Article Emcure Pharmaceuticals shares rose on Monday after the company’s board approved a scheme to merge its wholly owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, with itself.
Emcure Pharma gets USFDA approval
2 Min Read Emcure Pharma has received a United States Food and Drug Administration EIR for the Sanand formulations facility in Gujarat. In an exchange filing issued on August 8, the Pune-based drug maker said that its recieved the Establishment Inspection Report (EIR) after the USFDA inspected the company’s formulations facility located at Sanand, Ahmedabad. The US drug regulator conducted this inspection from May 06, 2026 to May 15, 2026.
Emcure gets India approval for MASH treatment
3 Min Read Pharmaceutical company Emcure Pharmaceuticals Ltd on Monday (July 20) announced that its co-marketed brand Poviztra can now be used for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following approval from the Central Drugs Standard Control Organisation (CDSCO).
Intelligence feed· 3 articles in 1440m
Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises
New: Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Story first reported.
Emcure Pharma surges 10%, stock hits new high on strong outlook
New: Emcure Pharma surges 10%, stock hits new high on strong outlook